Ciprofloxacin-Induced Vertigo and Tinnitus
Disabling vestibular and auditory symptoms during systemic fluoroquinolone therapy should prompt discontinuation of ciprofloxacin when feasible. [1] Otologic evaluation and urgent assessment for ongoing vestibular dysfunction are recommended for symptoms such as vertigo and tinnitus occurring during potentially ototoxic medication exposure. [1]
Immediate Management Steps
- Ciprofloxacin should be stopped immediately. [1]
- Medication-related adverse effects should be treated as urgent ototoxicity/vestibular toxicity because fluoroquinolones are potentially ototoxic. [1]
- An otolaryngology evaluation should be arranged for new tinnitus or vertigo occurring during therapy with a potentially ototoxic medication. [1]
- Neurologic adverse effects should be assessed in parallel with otologic symptoms, including evaluation for red flags that require emergency care (eg, severe neurologic deficits, persistent severe vertigo with inability to ambulate). [2]
- Adverse drug reaction reporting to pharmacovigilance systems should be performed per local policy. [2]
Alternative Antimicrobial Therapy Selection
Alternative antimicrobial therapy should be selected to treat the original infection using the patient’s indication, severity, pregnancy status, renal function, local resistance patterns, and prior antibiotic exposure. [3] Because ciprofloxacin has been stopped for suspected toxicity, a non-fluoroquinolone option should be used when empiric therapy must be continued before culture results return. [3]
Acute Uncomplicated Cystitis Alternative Therapy
First-line alternatives to fluoroquinolones for acute uncomplicated cystitis in women include the following options. [3]
- Nitrofurantoin. [3]
- Trimethoprim-sulfamethoxazole (only where community resistance levels are acceptable). [3]
-
Fosfomycin (single-dose option where available). [3] If preferred first-line agents cannot be used due to resistance or intolerance, several oral beta-lactam options may be used as alternatives, including. [3]
-
Amoxicillin-clavulanate. [3]
- Cefdinir. [3]
- Cefaclor. [3]
- Cefpodoxime. [3]
Acute Uncomplicated Pyelonephritis Alternative Therapy
Outpatient empiric oral fluoroquinolone therapy for acute uncomplicated pyelonephritis is recommended in existing IDSA guidance only when fluoroquinolones are appropriate. [4] When a fluoroquinolone is not appropriate due to intolerance or contraindication, an alternative approach recommended in the IDSA cystitis/pyelonephritis guideline summary includes the use of an initial parenteral agent for resistance coverage followed by an oral non-fluoroquinolone option when feasible. [3] Oral options after initial parenteral coverage may include trimethoprim-sulfamethoxazole or oral beta-lactams with appropriate limitations for efficacy compared with fluoroquinolones. [3]
Common Pitfalls to Avoid
- Ciprofloxacin should not be continued after vertigo or tinnitus develops because discontinuation is recommended when possible for auditory or vestibular symptoms during potentially ototoxic medications. [1]
- Switching to another fluoroquinolone without reassessing risk should be avoided because the adverse-effect mechanism is class-related and symptoms may persist or worsen after exposure. [1], [2]
- Delaying antimicrobial selection until culture confirmation should be avoided when the infection severity warrants immediate ongoing treatment. [3]
Targets for Clinical Follow-Up
- Symptom resolution and stability should be monitored after ciprofloxacin discontinuation. [1]
- Audiovestibular assessment should be completed through otolaryngology evaluation for persistent tinnitus or vertigo. [1]
- Antibiotic selection should be revisited once urine culture and susceptibility results are available. [3]